Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
Passage Bio (NASDAQ: PASG), a clinical-stage genetic medicines company specializing in neurodegenerative diseases, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City.
CEO Will Chou, M.D., will deliver a company overview presentation and the management team will engage in one-on-one investor meetings. The presentation will be available via video webcast to conference attendees starting September 5, 2025, at 7:00 a.m. ET, with a 30-day replay period accessible through the company's investor relations website.
Passage Bio (NASDAQ: PASG), azienda in fase clinica specializzata in terapie genetiche per le malattie neurodegenerative, ha comunicato la sua partecipazione al 27° H.C. Wainwright Annual Global Investment Conference, che si terrà dall'8 al 10 settembre 2025 a New York City.
Il CEO Will Chou, M.D., presenterà una panoramica aziendale e il team dirigenziale svolgerà incontri individuali con gli investitori. La presentazione sarà disponibile in webcast video per i partecipanti alla conferenza a partire dal 5 settembre 2025 alle 7:00 ET e potrà essere rivista per 30 giorni tramite il sito web delle relazioni con gli investitori della società.
Passage Bio (NASDAQ: PASG), una compañía en fase clínica especializada en medicinas genéticas para enfermedades neurodegenerativas, anunció su participación en la 27ª Conferencia Global Anual de Inversiones H.C. Wainwright, que se celebrará del 8 al 10 de septiembre de 2025 en la ciudad de Nueva York.
El director ejecutivo Will Chou, M.D., ofrecerá una presentación sobre la compañía y el equipo directivo llevará a cabo reuniones individuales con inversores. La presentación estará disponible en webcast en vídeo para los asistentes a la conferencia a partir del 5 de septiembre de 2025 a las 7:00 ET, con una reproducción disponible durante 30 días en el sitio web de relaciones con inversores de la empresa.
Passage Bio (NASDAQ: PASG), 신경퇴행성 질환을 전문으로 하는 임상 단계 유전자 치료 회사가 H.C. Wainwright 제27회 연례 글로벌 투자 컨퍼런스에 2025년 9월 8일부터 10일까지 뉴욕에서 참여한다고 발표했습니다.
CEO Will Chou 박사가 회사 개요 프레젠테이션을 진행하며 경영진은 투자자와 일대일 미팅을 가질 예정입니다. 프레젠테이션은 2025년 9월 5일 오전 7:00(동부시간)부터 컨퍼런스 참가자들이 시청할 수 있는 비디오 웹캐스트로 제공되며, 회사 IR 웹사이트를 통해 30일간 재시청이 가능합니다.
Passage Bio (NASDAQ: PASG), société en phase clinique spécialisée dans les médicaments génétiques pour les maladies neurodégénératives, a annoncé sa participation à la 27e conférence mondiale annuelle sur l'investissement H.C. Wainwright, qui se tiendra du 8 au 10 septembre 2025 à New York.
Le PDG Will Chou, M.D., présentera un aperçu de l'entreprise et l'équipe de direction tiendra des réunions individuelles avec des investisseurs. La présentation sera disponible en webcast vidéo pour les participants à la conférence à partir du 5 septembre 2025 à 7h00 ET, avec une rediffusion accessible pendant 30 jours via le site des relations investisseurs de la société.
Passage Bio (NASDAQ: PASG), ein klinisch operierendes Unternehmen für genetische Therapien mit Schwerpunkt auf neurodegenerativen Erkrankungen, gab seine Teilnahme an der 27. H.C. Wainwright Annual Global Investment Conference bekannt, die vom 8. bis 10. September 2025 in New York City stattfindet.
CEO Will Chou, M.D., wird eine Unternehmensübersicht präsentieren und das Management-Team wird Einzelgespräche mit Investoren führen. Die Präsentation wird für Konferenzteilnehmer ab dem 5. September 2025 um 7:00 Uhr ET als Video-Webcast verfügbar sein und kann über die Investor-Relations-Website des Unternehmens 30 Tage lang erneut aufgerufen werden.
- None.
- None.
PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held from September 8-10, 2025 in New York City.
Will Chou, M.D., president and chief executive officer, will present an overview of the company, and management will participate in one-on-one meetings with investors. A video webcast of the presentation will be available to registered conference attendees via the conference platform beginning Friday, September 5, 2025, at 7:00 a.m. ET and will be available on the Investors & News section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.
To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: passagebio.com.
For further information, please contact:
Investors:
Stuart Henderson
Passage Bio
shenderson@passagebio.com
Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com
FAQ
When is Passage Bio presenting at the H.C. Wainwright Conference 2025?
Who will be presenting for Passage Bio (PASG) at the H.C. Wainwright Conference?
How can investors access Passage Bio's H.C. Wainwright Conference presentation?
What is Passage Bio's (PASG) main business focus?
